[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.129.96. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
March 17, 2004

ApoA-1 Milano and Regression of Atherosclerosis—Reply

Author Affiliations
 

Letters Section Editor: Stephen J. Lurie, MD, PhD, Senior Editor.

JAMA. 2004;291(11):1319-1320. doi:10.1001/jama.291.11.1320-a

In Reply: We agree with Dr Kim and colleagues that it is unlikely that HDL particle size represents the protective mechanism underlying the observed effects of ETC-216. Kim et al also point out the absence of a well-defined mechanistic explanation for the observed benefits of ApoA-1 Milano in carriers or following therapeutic administration. Now that we have preliminary evidence of a rapid regression of atherosclerosis in human subjects, we hope that our study will encourage further exploration of the molecular and cellular mechanisms of action of ApoA-1 Milano. Such efforts could provide important insights into the process of reverse cholesterol transport and lead to development of other approaches to achieve regression of coronary disease. Currently, the same team that developed ETC-216 is beginning human studies of a small molecule that appears to provide similar benefits and would be much easier to manufacture than a recombinant protein such as ApoA-1 Milano. If this peptide mimetic produces similar results to ETC-216 in human studies, it would establish the principle that the full ApoA-1 protein is not required to activate the reverse cholesterol transport system.

First Page Preview View Large
First page PDF preview
First page PDF preview
×